MedTrace Logo

AIMHI NT Relapse Prevention Trial

NCT00192582 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2007-05-22

No results posted yet for this study

Summary

A new treatment for indigenous people with mental illness in remote communities has been developed. The study hypothesis is that this new treatment will result in better outcomes for clients and carers than the outcomes of clients and carers who do not receive the treatment. The treatment is a combination of a talking treatment and sharing of stories about mental health. The treatment will be delivered to the client with their chosen carer and with the local Aboriginal Mental Health Worker or Health Worker. The treatment will be given by the research team - a psychiatrist and an indigenous research officer. The trial will compare two groups of clients - a control group which is receiving 'treatment as usual', and the group which receives the new treatment. Measures of social functioning and symptoms of mental illness will be administered at base line and every six months for two years.

Conditions

Interventions

BEHAVIORAL

Motivational Interview with care plan and education

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Alcohol Education and rehabilitation Fund

    collaborator OTHER

  • Cooperative Research Centre for Aboriginal Health

    collaborator OTHER

  • Northern Territory Government of Australia

    collaborator OTHER_GOV

  • Menzies School of Health Research

    lead OTHER

Principal Investigators

  • Tricia M Nagel, MBBS, FRANZCP · Menzies School of Health Research, Australia

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2007-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00192582 on ClinicalTrials.gov